MabSpace and Hengrui link up to develop novel antibody therapeutics

Published: 20-May-2015
Research & Development

MabSpace will discover and select humanised lead antibodies, while Hengrui will receive exclusive global rights to the resulting therapeutic candidates


Hong Kong-based biotechnology company-MabSpace Biosciences has signed a contract with Chinese pharmaceutical company Jiangsu Hengrui Medicine Co, to jointly develop novel antibody therapeutics on two targets.

Under the agreement, MabSpace will be responsible for the discovery and selection of humanised lead antibodies, while Hengrui will receive exclusive global rights to the resulting therapeutic candidates for the nominated targets, and will further develop the selected candidates.

  • Companies:
  • Jiangsu Hengrui Medicine Co. Ltd
See more

You may also like

Research & Development

Compact process thermostat for efficient temperature control in the laboratory

Read more
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C

Trending Articles

  1. Naobios and Sumagen sign exclusive partnership to develop HIV vaccine Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
  2. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  3. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
  4. Cresset creates new Vice President role to lead its AI strategy Dr Mutlu Dogruel joins from Microsoft, where he was responsible for empowering organisations to implement scalable AI solutions into their workflow
  5. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

Compact process thermostat for efficient temperature control in the laboratory

The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
Manufacturing

ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year

The award recognises employers that create an outstanding experience for employees
Manufacturing

Rapid increase in purchasing teams expected at CPHI North America

Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
Manufacturing

Naobios and Sumagen sign exclusive partnership to develop HIV vaccine

Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Research & Development

Serum Institute of India collaborates with Univercells to enhance availability of affordable personalised oncology

The partnership endeavours to speed up development times and distribute personalised cancer vaccines to all locations globally, rather than just economically developed countries
Research & Development

Exeliom Biosciences announces three Phase II immuno-oncology clinical trials

Phase II clinical trials will investigate efficacy of lead candidate EXL01 – in gastric cancer with GERCOR, in NSCLC with CHU Lille and in hepatocellular carcinoma with Centre Eugène Marquis of Rennes
Subscribe now